[Clinico-immunologic aspects of the differentiated use of plasma substitutes in the complex treatment of various bronchopulmonary diseases].
The authors present some theoretical and experimental prerequisites for differentiated use of hemodez, rheopolyglucin and gelatinol in asthma, chronic bronchitis and pneumonia. A positive effect of the agents including low- and medium-molecular polymers on the clinical and immunological indices of 82 patients with bronchopulmonary pathology was shown as compared to corresponding control groups. Clinico-immunological studies on the use of drugs containing synthetic and biological polymers revealed their high immunomodulating activity and necessity of differentiated use of these drugs with relation to the pathogenetic mechanisms of development of bronchopulmonary diseases as well as mechanisms of their immunological action determined by the molecular mass of polymers as constituents of blood substitutes.